

# Fatal Toxic Effects Associated With Immune Checkpoint

JAMA Oncology

4, 1721

DOI: [10.1001/jamaoncol.2018.3923](https://doi.org/10.1001/jamaoncol.2018.3923)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors: fatal toxic effects. <i>Reactions Weekly</i> , 2018, 1721, 8-8.	0.0	3
2	Arterial events in cancer patients—the case of acute coronary thrombosis. <i>Journal of Thoracic Disease</i> , 2018, 10, S4367-S4385.	0.6	31
4	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	5.1	742
5	Updates on Immunotherapy for the Treatment of Skin Cancer. <i>Current Dermatology Reports</i> , 2018, 7, 311-320.	1.1	2
7	Insights into the risk of fatal AEs with ICIs. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 653-653.	12.5	0
8	Immunotherapy Adverse Events: An Emergency Nursing Perspective. <i>Journal of Emergency Nursing</i> , 2019, 45, 699-706.	0.5	1
9	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	1.9	31
10	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
11	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
12	The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma. <i>Melanoma Management</i> , 2019, 6, MMT16.	0.1	2
13	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	2.0	42
14	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	1.1	7
15	Clinical significance of signs of autoimmune colitis in <sup>18</sup> F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. <i>Immunotherapy</i> , 2019, 11, 667-676.	1.0	41
16	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 588-596.	0.4	43
18	Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review. <i>International Journal of Cardiology</i> , 2019, 296, 113-121.	0.8	34
19	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. <i>Liver International</i> , 2019, 39, 1608-1621.	1.9	67
20	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
21	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	15.2	133

#	ARTICLE	IF	CITATIONS
22	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 524-532.	0.9	38
23	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 800-808.	1.9	60
24	Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1865-1878.	1.4	49
25	Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. <i>Melanoma Management</i> , 2019, 6, MMT13.	0.1	13
26	Germinal immunogenetics as a predictive factor for immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 146-152.	2.0	5
27	Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1689-1693.	0.2	8
28	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
29	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 972.	1.3	17
30	Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
31	Comparison of drug safety data obtained from the monitoring system, literature, and social media: An empirical proof from a Chinese patent medicine. <i>PLoS ONE</i> , 2019, 14, e0222077.	1.1	4
32	The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2019, 77, 105975.	1.7	7
33	Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. , 2019, 7, 286.		92
34	Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. <i>Cell Death and Disease</i> , 2019, 10, 836.	2.7	29
35	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
36	Small molecules as theranostic agents in cancer immunology. <i>Theranostics</i> , 2019, 9, 7849-7871.	4.6	42
37	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1254.	1.6	21
38	Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. <i>Critical Reviews in Immunology</i> , 2019, 39, 93-103.	1.0	16
39	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53

#	ARTICLE	IF	CITATIONS
40	Emerging agents and regimens for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 110.	6.9	71
41	Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. <i>Nutrients</i> , 2019, 11, 2547.	1.7	12
42	Study on the Rule of Concrete Corrosion in Harsh Environment. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 304, 052002.	0.2	1
43	Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. <i>Journal of Neuro-Oncology</i> , 2019, 145, 1-9.	1.4	69
45	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
46	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2019, 79, 101887.	3.4	49
47	Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: Same disease, distinct challenges to face. <i>International Journal of Cardiology</i> , 2019, 296, 124-126.	0.8	9
48	Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e1911519.	2.8	57
49	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
50	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	2.5	97
51	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4
52	Imaging of myocarditis and inflammatory cardiomyopathies. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 630-641.	0.7	21
53	Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2019, 104, 102333.	3.0	70
54	Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition. <i>European Journal of Cancer</i> , 2019, 121, 1-3.	1.3	2
55	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	3.7	28
56	Immune checkpoint inhibitor-related luminal GI adverse events. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 881-892.	0.5	24
57	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150926.	0.7	7
58	Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 905-912.	1.3	78

#	ARTICLE	IF	CITATIONS
59	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 765-774.	1.2	35
60	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
61	Success of immune checkpoint blockade therapies â€œ mechanisms and implications for hepatology. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 74-86.	0.2	2
62	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3957-3969.	0.9	5
63	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
64	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.4	42
65	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019, 5, 112-118.	1.2	39
66	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	0.8	44
67	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
68	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e120-e120.	0.5	15
69	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
70	Approaches to High-Risk Resected Stage II and III Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e207-e211.	1.8	18
71	Immunotherapy in Older Adults with Cancer. <i>Current Oncology Reports</i> , 2019, 21, 56.	1.8	16
72	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e110-e120.	1.8	11
73	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
74	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
75	The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective. <i>Antibody Therapeutics</i> , 2019, 2, 40-43.	1.2	2
76	Immune Checkpoint Inhibitorâ€™Associated Pericarditis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1102-1108.	0.5	72

#	ARTICLE	IF	CITATIONS
77	Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.	0.9	52
78	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
79	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
80	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36
81	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
82	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305.	1.7	51
83	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
84	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. <i>Current Treatment Options in Oncology</i> , 2019, 20, 35.	1.3	44
85	Immunotherapy for small cell lung cancer: mechanisms of resistance. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 423-432.	1.4	53
87	Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent <i>Clostridium Difficile</i> Infection. <i>Case Reports in Oncology</i> , 2019, 12, 164-170.	0.3	15
88	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
89	Adverse events 2.0—Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
90	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. <i>Nano Letters</i> , 2019, 19, 2935-2944.	4.5	134
91	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
92	&lt;p&gt;Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients&lt;p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 211-221.	0.9	42
93	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
94	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.	1.4	7
95	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	1.9	81

#	ARTICLE	IF	CITATIONS
96	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
97	Anti-PD-1 Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. <i>Cancer Immunology Research</i> , 2019, 7, 1755-1759.	1.6	20
98	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. <i>Oncologist</i> , 2019, 24, 872-876.	1.9	38
99	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
100	Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature. <i>Journal of Immunotherapy</i> , 2019, 42, 313-317.	1.2	11
101	Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1331-1340.	2.1	49
102	Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1300.	1.6	12
103	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
104	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	0.6	2
105	Checkpoint Inhibitor-Associated Autoimmunity. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	0
106	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75
107	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
108	Developing neoantigen-targeted T cell-based treatments for solid tumors. <i>Nature Medicine</i> , 2019, 25, 1488-1499.	15.2	173
109	Immune checkpoint inhibitors. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 426-433.	1.3	8
110	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. <i>Clinical Cancer Research</i> , 2019, 25, 1452-1454.	3.2	33
111	Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide. <i>European Journal of Cancer</i> , 2019, 107, 97-99.	1.3	12
112	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
113	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , 2019, 20, e54-e64.	5.1	149

#	ARTICLE	IF	CITATIONS
114	Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo. <i>Science and Technology Libraries</i> , 2019, 38, 1-29.	0.8	0
115	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
116	Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 133-140.	0.5	1
117	Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 160-171.	1.2	30
118	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , 2020, 64, 93-101.	4.3	135
119	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. <i>Journal of Rheumatology</i> , 2020, 47, 166-175.	1.0	47
120	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. <i>Histopathology</i> , 2020, 76, 233-243.	1.6	66
121	Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 299-308.	0.9	38
122	Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e74-e77.	1.1	16
123	Principles of Immunotherapy in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 161-173.	0.5	28
124	Interaction and assembly processes of abundant and rare microbial communities during a diatom bloom process. <i>Environmental Microbiology</i> , 2020, 22, 1707-1719.	1.8	60
126	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13
127	Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. <i>Human Pathology</i> , 2020, 96, 39-47.	1.1	17
128	Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. <i>Lung Cancer</i> , 2020, 140, 116-117.	0.9	3
129	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. <i>Journal of Virology</i> , 2020, 94, .	1.5	54
130	Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. <i>Lancet Oncology</i> , The, 2020, 21, e55-e65.	5.1	59
131	Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 1200-1206.	1.2	52
132	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. <i>Canadian Journal of Cardiology</i> , 2020, 36, 476-481.	0.8	40

#	ARTICLE	IF	CITATIONS
133	Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncology, 2020, 101, 104492.	0.8	44
134	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine, 2020, 48, 10-21.	0.4	42
135	Immune-checkpoint inhibitors induced diarrhea and colitis. Current Opinion in Gastroenterology, 2020, 36, 25-32.	1.0	21
136	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 1-7.	1.2	75
137	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	0.8	135
138	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
139	Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. Clinics in Liver Disease, 2020, 24, 89-106.	1.0	13
140	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. Life Sciences, 2020, 240, 117093.	2.0	12
141	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thoracic Cancer, 2020, 11, 475-480.	0.8	9
142	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 291-298.	0.7	21
143	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. International Journal of Molecular Sciences, 2020, 21, 7195.	1.8	55
144	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunology Research, 2020, 8, 1230-1235.	1.6	10
145	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. Current Opinion in Oncology, 2020, 32, 603-612.	1.1	5
146	Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962096501.	0.3	3
147	<p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. Cancer Management and Research, 2020, Volume 12, 9389-9403.	0.9	8
148	Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Scientific Reports, 2020, 10, 15567.	1.6	20
149	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Pharmacological Research, 2020, 160, 105194.	3.1	13
150	Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thrombosis Research, 2020, 196, 444-453.	0.8	55

#	ARTICLE	IF	CITATIONS
151	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
152	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
153	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	2.6	86
154	Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. <i>Oncologist</i> , 2020, 25, 1009-1012.	1.9	10
155	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	1.3	44
156	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	5.8	120
157	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	1.1	5
158	Uses of pharmacovigilance databases: An overview. <i>Therapie</i> , 2020, 75, 591-598.	0.6	92
159	Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 659-663.	0.3	15
160	A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapyâ€Related Toxicity: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2020, 215, 770-780.	1.0	4
161	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
162	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <i>Gastroenterology</i> , 2020, 159, 1195-1200.e1.	0.6	5
163	Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation. <i>Acta Clinica Belgica</i> , 2022, 77, 51-58.	0.5	5
164	Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 696-701.	0.3	7
165	A promising treatment option for refractory male primary choriocarcinoma: report of two cases. <i>Translational Cancer Research</i> , 2020, 9, 3054-3060.	0.4	11
166	Novel systemic therapy for hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 638-651.	1.9	15
167	Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 935-944.	1.3	27
168	Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy. , 2020, 8, e001687.		11

#	ARTICLE	IF	CITATIONS
169	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	1.3	9
170	Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2097222.	0.2	5
171	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
172	The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. <i>BMC Cancer</i> , 2020, 20, 1128.	1.1	7
173	<p>Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11725-11740.	1.0	25
174	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <i>Future Science OA</i> , 2020, 6, FSO600.	0.9	9
175	A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1253-1253.	0.7	3
176	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
177	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9056.	1.8	19
178	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	2.0	14
179	Immunosenescence: a key player in cancer development. <i>Journal of Hematology and Oncology</i> , 2020, 13, 151.	6.9	198
180	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American Heart Association</i> , 2020, 9, e018306.	1.6	38
181	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 572329.	1.3	7
182	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 511-514.	1.7	8
183	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
184	MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1683-1689.	1.2	22
185	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
186	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	1.7	7

#	ARTICLE	IF	CITATIONS
187	Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1261-1264.	0.5	6
189	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	1.3	21
190	ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	1.0	6
191	Pulmonary toxicity of systemic lung cancer therapy. <i>Respirology</i> , 2020, 25, 72-79.	1.3	42
192	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	0.9	24
193	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <i>Journal of Hematology and Oncology</i> , 2020, 13, 105.	6.9	73
194	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	1.7	86
195	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 335-352.	1.1	20
196	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2403-2408.	2.0	10
197	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	5.1	74
198	Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2020, 8, 778-778.	0.7	1
199	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3804-3818.	0.4	7
200	A decade of immune-checkpoint inhibitors in cancer therapy. <i>Nature Communications</i> , 2020, 11, 3801.	5.8	920
201	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa069.	0.1	14
202	Immune checkpoint inhibitor-related cutaneous adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e149-e153.	0.7	7
203	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
204	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	1.0	6
205	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 171.	1.3	8

#	ARTICLE	IF	CITATIONS
206	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
207	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
208	How we treat neurological toxicity from immune checkpoint inhibitors. <i>ESMO Open</i> , 2020, 4, e000540.	2.0	25
209	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	1.0	11
210	Hemophagocytic syndrome associated with pembrolizumab therapy successfully controlled by cyclosporin. <i>Journal of Dermatology</i> , 2020, 47, e422-e423.	0.6	2
211	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1183-1193.	1.0	12
212	Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1279-1294.	0.9	28
213	Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	0
214	Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 652-655.	0.5	2
215	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 432-440.	1.0	4
217	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage <scp>III</scp> non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 2916-2923.	0.8	7
218	Nucleic Acid-Based Approaches for Tumor Therapy. <i>Cells</i> , 2020, 9, 2061.	1.8	40
219	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	1.2	4
220	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	1.3	32
221	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
222	COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1133-1138.	1.0	10
223	Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma. <i>Melanoma Research</i> , 2020, 30, 484-491.	0.6	10
224	ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4208-e4218.	1.8	15

#	ARTICLE	IF	CITATIONS
225	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
226	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
227	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091380.	1.4	10
228	&lt;p&gt;A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
229	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	1.3	5
230	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
231	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , 2020, 5, e000866.	2.0	34
232	Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. <i>Cells</i> , 2020, 9, 1896.	1.8	73
233	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. , 2020, 8, e001887.		45
234	Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. <i>Frontiers in Oncology</i> , 2020, 10, 583781.	1.3	6
235	By Releasing the Brakes With Immunotherapy, Are We Accelerating Atherosclerosis?. <i>Circulation</i> , 2020, 142, 2312-2315.	1.6	9
236	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 284.	3.5	67
237	Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. <i>Frontiers in Neurology</i> , 2020, 11, 538695.	1.1	37
238	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
239	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 541-547.	0.1	0
240	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
241	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	13
242	Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 287.	7.1	72

#	ARTICLE	IF	CITATIONS
243	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
244	Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report. <i>In Vivo</i> , 2020, 34, 1475-1480.	0.6	4
245	Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 77-89.	0.3	7
246	Cardiotoxicity danger in immunotherapy. <i>IUBMB Life</i> , 2020, 72, 1160-1167.	1.5	4
247	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 851-855.	1.6	37
248	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.	1.5	74
249	Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. <i>Annals of Oncology</i> , 2020, 31, 1273-1275.	0.6	44
250	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
251	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO Vigibase Report Analysis. <i>Oncologist</i> , 2020, 25, 696-701.	1.9	73
252	Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. <i>Hematological Oncology</i> , 2020, 38, 565-575.	0.8	22
253	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	6.9	84
254	Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary. <i>Journal of Dermatology</i> , 2020, 47, e237-e239.	0.6	3
255	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	1.1	7
256	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
257	Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. <i>International Journal of Chronic Diseases</i> , 2020, 2020, 1-5.	1.9	1
258	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	1.3	20
259	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020, 22, 56.	1.8	23
260	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1255-1268.	0.6	221

#	ARTICLE	IF	CITATIONS
261	latrogenesis and neurological manifestations in the elderly. <i>Revue Neurologique</i> , 2020, 176, 710-723.	0.6	4
262	Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. <i>Immunotherapy</i> , 2020, 12, 531-540.	1.0	2
263	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
264	Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma. <i>Cancers</i> , 2020, 12, 1321.	1.7	11
265	A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. <i>Current Oncology</i> , 2020, 27, 87-97.	0.9	554
266	Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 2374-2375.	13.9	54
267	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	0.4	16
268	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	2.5	80
269	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. <i>Autoimmunity Reviews</i> , 2020, 19, 102590.	2.5	37
270	&lt;p&gt;Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	0.9	29
271	Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy. <i>Chemical Engineering Journal</i> , 2020, 400, 125995.	6.6	36
272	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
273	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
274	Pulmonary Complications of Immunotherapy. <i>Clinics in Chest Medicine</i> , 2020, 41, 295-305.	0.8	1
275	Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. , 2020, 8, e000266.		69
276	Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1023-1031.	0.6	8
277	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
278	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	0.9	8

#	ARTICLE	IF	CITATIONS
279	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
280	ADRB3 expression in tumor cells is a poor prognostic factor and promotes proliferation in non-small cell lung carcinoma. Cancer Immunology, Immunotherapy, 2020, 69, 2345-2355.	2.0	6
281	New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Current Oncology Reports, 2020, 22, 65.	1.8	44
282	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Frontiers in Pharmacology, 2020, 11, 830.	1.6	21
283	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345.	1.1	38
284	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm, 2020, 1, 47-68.	3.1	93
285	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Current Gastroenterology Reports, 2020, 22, 15.	1.1	20
286	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. New England Journal of Medicine, 2020, 382, 1150-1159.	13.9	7
287	The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. BMC Biology, 2020, 18, 29.	1.7	6
288	Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. European Journal of Cancer, 2020, 128, 57-59.	1.3	7
289	Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy. Cancer Medicine, 2020, 9, 3070-3077.	1.3	17
290	Neurologic complications of immune checkpoint inhibitors. Expert Opinion on Drug Safety, 2020, 19, 479-488.	1.0	82
291	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Internal and Emergency Medicine, 2020, 15, 587-598.	1.0	16
292	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology, 2020, 213, 108377.	1.4	44
293	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 197.	1.3	9
294	A Fatal Case of Pembrolizumab-Induced Myocarditis in Non-Small Cell Lung Cancer. JACC: Case Reports, 2020, 2, 426-430.	0.3	7
295	Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. Internal Medicine, 2020, 59, 1075-1080.	0.3	16
296	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 2020, 22, 39.	1.8	199

#	ARTICLE	IF	CITATIONS
297	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 269-273.	1.0	188
298	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <i>Nature Reviews Cardiology</i> , 2020, 17, 474-502.	6.1	332
299	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	12.5	189
300	TGF-beta: a master immune regulator. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 427-438.	1.5	101
301	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
302	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329.	3.6	131
303	The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	1.3	37
304	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
305	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 451-464.	1.6	63
306	Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 43-48.	0.3	7
307	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	2.0	0
308	Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature. <i>Case Reports in Oncology</i> , 2020, 13, 621-626.	0.3	16
309	Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma. <i>Diagnostics</i> , 2020, 10, 410.	1.3	5
310	Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2020, 54, 1-10.	1.7	35
311	Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
312	Evolution of Immune Checkpoint Blockade—Induced Myocarditis Over 2 Years. <i>JACC: Case Reports</i> , 2020, 2, 203-209.	0.3	5
313	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	2.0	28
314	Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry. <i>Immuno-Oncology Technology</i> , 2020, 6, 2-8.	0.2	26

#	ARTICLE	IF	CITATIONS
315	The Contribution of Epigenetics to Cancer Immunotherapy. Trends in Immunology, 2020, 41, 676-691.	2.9	133
316	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecologic Oncology, 2020, 158, 531-537.	0.6	8
317	Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257.	1.0	2
318	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. Immunology Letters, 2020, 221, 61-71.	1.1	12
319	Polymorphism of toll-like receptor genes and autoimmune endocrine diseases. Autoimmunity Reviews, 2020, 19, 102496.	2.5	28
320	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology, 2020, 9, 1722023.	2.1	37
321	Checkpoint Inhibitor-Induced Colitis. American Journal of Gastroenterology, 2020, 115, 202-210.	0.2	68
322	Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2019, 10, 1671.	1.6	40
323	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 5.	1.6	12
324	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of Neurology, 2020, 87, 659-669.	2.8	137
326	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. Journal of the American College of Cardiology, 2020, 75, 620-628.	1.2	49
327	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	1.0	212
328	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. European Respiratory Journal, 2020, 55, 2000038.	3.1	19
329	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Translational Oncology, 2020, 13, 100738.	1.7	173
330	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310
331	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	157.7	753
332	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Research, 2020, 30, 285-299.	5.7	129
333	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Annals of Surgical Oncology, 2020, 27, 1533-1545.	0.7	6

#	ARTICLE	IF	CITATIONS
334	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
335	Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report. <i>Cardiovascular Pathology</i> , 2020, 46, 107202.	0.7	25
336	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , 2020, 38, 130-138.	0.6	14
337	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10
338	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
339	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
340	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	2.4	47
341	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
342	Aberrant sialylation in ovarian cancers. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 337-344.	0.6	42
344	Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1473-1483.	1.8	23
345	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. <i>European Journal of Cancer</i> , 2020, 131, 18-26.	1.3	50
346	Advances in living cell-based anticancer therapeutics. <i>Biomaterials Science</i> , 2020, 8, 2344-2365.	2.6	22
347	Autoimmune complications of immunotherapy: pathophysiology and management. <i>BMJ, The</i> , 2020, 369, m736.	3.0	79
348	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2020, 10, 216.	1.3	13
349	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <i>Liver International</i> , 2020, 40, 1906-1916.	1.9	43
350	Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1737-1749.	2.0	6
351	Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review. <i>European Journal of Cancer</i> , 2020, 130, 20-22.	1.3	1
353	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	3.4	295

#	ARTICLE	IF	CITATIONS
355	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101511.	1.4	3
356	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454.	3.0	11
357	A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2020, 99, e19741.	0.4	19
358	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	3.2	112
359	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD1-Resistant Model of Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	1.6	48
360	Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. <i>BMC Medicine</i> , 2020, 18, 87.	2.3	189
361	A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 16-16.	0.4	23
362	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. <i>PLoS Pathogens</i> , 2020, 16, e1008340.	2.1	11
363	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 258.	1.3	35
364	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	0.5	6
365	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
366	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 527-541.	1.1	5
367	Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e109-e116.	0.7	6
368	Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. <i>Archives of Dermatological Research</i> , 2021, 313, 1-10.	1.1	14
369	Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. <i>Clinical and Translational Oncology</i> , 2021, 23, 389-396.	1.2	17
370	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	1.5	24
371	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 739-746.	0.5	18
372	New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 716-721.	0.5	12

#	ARTICLE	IF	CITATIONS
373	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology, 2021, 61, 113-134.	4.2	40
374	Hepatitis B reactivation and immune check point inhibitors. Digestive and Liver Disease, 2021, 53, 452-455.	0.4	15
375	Improving safety of cancer immunotherapy via delivery technology. Biomaterials, 2021, 265, 120407.	5.7	22
376	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833.	2.9	6
377	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology, 2021, 160, 1384-1393.	0.6	121
378	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54.	4.4	31
379	Is Viral Vector Gene Delivery More Effective Using Biomaterials?. Advanced Healthcare Materials, 2021, 10, e2001238.	3.9	34
380	Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. Cancer Immunology, Immunotherapy, 2021, 70, 1527-1540.	2.0	21
381	Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy. Neuro-Oncology Practice, 2021, 8, 247-258.	1.0	3
382	Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 157, 103162.	2.0	1
383	Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockade. Journal of Chemotherapy, 2021, 33, 32-39.	0.7	9
384	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. Critical Care Clinics, 2021, 37, 47-67.	1.0	5
385	Frontiers in cancer immunotherapy—a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47.	1.8	39
386	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Medicine, 2021, 10, 188-198.	1.3	11
387	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2021, 12, 153-164.	0.8	28
388	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 2021, 16, 381-394.	0.5	12
389	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. European Heart Journal, 2021, 42, 1621-1631.	1.0	102
390	Cardiotoxicity Related to Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
391	Promising novel therapies for relapsed and refractory testicular germ cell tumors. Expert Review of Anticancer Therapy, 2021, 21, 53-69.	1.1	4
392	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 13-28.	0.7	1
393	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. EBioMedicine, 2021, 63, 103137.	2.7	44
394	Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects. Expert Opinion on Drug Delivery, 2021, 18, 333-354.	2.4	17
395	Oncologic Emergencies. Critical Care Clinics, 2021, 37, 85-103.	1.0	13
396	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112.	4.2	50
397	Emerging cancer therapies and cardiovascular risk. Journal of Thrombosis and Thrombolysis, 2021, 51, 837-845.	1.0	0
398	Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-Î² accumulation and improves cognition in APP/PS1 mice. Brain, Behavior, and Immunity, 2021, 91, 128-141.	2.0	16
399	Tâ€cell responses and therapies against SARSâ€CoVâ€2 infection. Immunology, 2021, 162, 30-43.	2.0	159
400	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. Acta Clinica Belgica, 2021, 76, 144-148.	0.5	2
401	Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature. Cureus, 2021, 13, e13034.	0.2	8
402	Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy. Chinese Medical Journal, 2021, 134, 780-782.	0.9	1
403	PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. Cancer Treatment and Research Communications, 2021, 28, 100379.	0.7	2
404	Fatal Immune Checkpoint Inhibitor-related Pancreatitis. Internal Medicine, 2021, 60, 3905-3911.	0.3	15
405	Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection. Cancer Immunology, Immunotherapy, 2021, 70, 2385-2388.	2.0	3
406	Review of immune checkpoint inhibitors in immuno-oncology. Advances in Pharmacology, 2021, 91, 111-139.	1.2	43
407	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. Reviews on Recent Clinical Trials, 2021, 15, 339-346.	0.4	5
408	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. British Journal of Surgery, 2021, 108, 1417-1425.	0.1	57

#	ARTICLE	IF	CITATIONS
409	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
411	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
412	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2209-2221.	2.0	32
413	Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review. Open Medicine (Poland), 2021, 16, 553-557.	0.6	5
414	Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?. Gastroenterología Y Hepatología, 2021, 44, 28-29.	0.2	1
415	Infections, Immunodeficiency, and Complications of Immunomodulatory Therapies in Neuroimmunology. , 2021, , 405-415.		0
416	Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management. Urology Case Reports, 2021, 34, 101508.	0.1	19
417	Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Annals of Palliative Medicine, 2021, 10, 793-802.	0.5	12
418	Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer, 2021, 21, 38.	1.1	17
419	Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. Journal of Neuro-Oncology, 2021, 152, 135-144.	1.4	45
420	Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. Current Cardiology Reports, 2021, 23, 16.	1.3	12
421	Infection: Myocarditis. , 2021, , 191-232.		0
422	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. JMA Journal, 2021, 4, 91-98.	0.6	13
423	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2021, 1, 1tab014.	1.2	10
424	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	1.8	38
425	Immunotherapy-induced colitis: Could it be ulcerative colitis?. Gastroenterología Y Hepatología (English Edition), 2021, 44, 28-29.	0.0	1
426	Comorbidity and frailty assessment in renal cell carcinoma patients. World Journal of Urology, 2021, 39, 2831-2841.	1.2	7
427	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology, Immunotherapy, 2021, 70, 2761-2769.	2.0	7

#	ARTICLE	IF	CITATIONS
428	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Expert Review of Anticancer Therapy, 2021, 21, 583-590.	1.1	4
429	First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Reports, 2021, 14, e238851.	0.2	15
430	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Frontiers in Pharmacology, 2021, 12, 616505.	1.6	23
431	Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT. Frontiers in Cardiovascular Medicine, 2021, 8, 614997.	1.1	55
432	Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events. Journal of Thoracic Oncology, 2021, 16, 183-186.	0.5	4
433	Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database. Journal of Zhejiang University: Science B, 2021, 22, 156-164.	1.3	6
434	Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 627089.	1.2	9
435	Reações Adversas Imunomediadas em pacientes tratados com Inibidores de Checkpoints Imunológicos em um Hospital filantrópico de Salvador. Research, Society and Development, 2021, 10, e58510212928.	0.0	0
436	Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. , 2021, 9, e002252.		1
437	Applying artificial intelligence for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 3393-3405.	5.7	33
438	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
439	Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. Frontiers in Immunology, 2021, 12, 615930.	2.2	12
440	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2559-2576.	2.0	40
441	Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors. Seminars in Ophthalmology, 2021, 36, 241-249.	0.8	6
442	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. American Journal of Roentgenology, 2021, , 1-9.	1.0	7
443	Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. Cancers, 2021, 13, 564.	1.7	46
444	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. Frontiers in Oncology, 2020, 10, 585311.	1.3	69
445	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38

#	ARTICLE	IF	CITATIONS
446	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111
447	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
448	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1469-1488.	0.8	7
449	A case series on the safety of immunotherapy with reduced blood testing frequency in lung cancer patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 851-857.	1.0	0
450	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
451	TNF in the era of immune checkpoint inhibitors: friend or foe?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 213-223.	3.5	77
452	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	3.6	53
453	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
454	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiototoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
455	Endokrynologiczne powikłania nowych terapii przeciwnowotworowych. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 191-198.	0.1	0
456	Long-Term Survivors of Breast Cancer: A Growing Population. , 0, , .		0
457	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	16
458	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021, 11, 607531.	1.3	18
459	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	3.0	56
460	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
461	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Medical Clinics of North America</i> , 2021, 105, 227-245.	1.1	3
462	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
463	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <i>ENeurologicalSci</i> , 2021, 22, 100324.	0.5	9

#	ARTICLE	IF	CITATIONS
464	CMR Parametric Mapping in Immune Checkpoint Inhibitor Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1517-1519.	1.2	3
465	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.4	53
466	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clinical Science, 2021, 135, 703-724.	1.8	18
467	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2021, 20, 651-667.	1.0	4
468	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin $\alpha$ 4 therapy. European Journal of Cancer, 2021, 145, 230-233.	1.3	6
469	Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anti-Cancer Drugs, 2021, 32, 567-574.	0.7	3
470	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	0.6	25
471	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. Translational Andrology and Urology, 2021, 10, 1541-1552.	0.6	6
472	Immune Checkpoint Inhibitors in the Treatment of Cancer. Current Clinical Pharmacology, 2022, 17, 103-113.	0.2	18
473	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	1.2	97
474	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. Frontiers in Oncology, 2021, 11, 642110.	1.3	32
475	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Scientific Reports, 2021, 11, 9029.	1.6	39
476	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clinical and Translational Oncology, 2021, 23, 1885-1904.	1.2	11
477	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. European Journal of Dermatology, 2021, 31, 205-212.	0.3	3
478	The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. Immunotherapy, 2021, 13, 527-539.	1.0	12
479	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Frontiers in Oncology, 2021, 11, 633032.	1.3	53
480	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	1.0	8
481	Immune Checkpoint Inhibitor-Related Adrenal Insufficiency. Seminars in Oncology Nursing, 2021, 37, 151131.	0.7	2

#	ARTICLE	IF	CITATIONS
483	Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 62-66.	0.7	3
484	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. <i>Clinical Radiology</i> , 2021, 76, 247-261.	0.5	0
485	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. <i>Cancers</i> , 2021, 13, 1794.	1.7	38
486	Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. <i>Medicine (United States)</i> , 2021, 100, e25402.	0.4	2
487	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
488	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
489	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
490	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1623-1630.	1.2	24
491	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	0
492	Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma. <i>Annals of the American Thoracic Society</i> , 2021, 18, 884-888.	1.5	1
493	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	1.8	85
494	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3003-3017.	0.7	4
495	Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded <i>Escherichia coli</i> Combined with Immunogenic Cell Death for Cancer Immunotherapy. <i>Nano Letters</i> , 2021, 21, 4231-4240.	4.5	149
496	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	3.4	110
497	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
498	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
499	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
500	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648.	2.0	46

#	ARTICLE	IF	CITATIONS
501	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	1.6	76
503	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2021, 11, 785.	1.8	9
504	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. <i>European Journal of Cancer</i> , 2021, 149, 105-113.	1.3	4
506	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	1.3	2
507	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
508	The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 386-394.	1.1	6
509	Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 33-33.	0.5	9
510	Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. <i>Nature Communications</i> , 2021, 12, 2637.	5.8	25
511	Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 619385.	1.3	12
512	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.2	1
513	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
514	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
515	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIIm) – insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	0.8	3
516	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	1.7	2
517	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. <i>Cancers</i> , 2021, 13, 2316.	1.7	5
518	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
519	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
520	Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 268-275.	0.6	7

#	ARTICLE	IF	CITATIONS
521	Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. <i>Frontiers in Oncology</i> , 2021, 11, 640985.	1.3	9
522	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2021, 7, 19.	0.8	14
523	Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100739.	0.3	7
524	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. <i>British Journal of Dermatology</i> , 2021, 185, 627-635.	1.4	12
525	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	1.7	15
526	Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. , 2021, 9, e002916.		29
527	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
528	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. <i>European Radiology</i> , 2021, 31, 8868-8878.	2.3	2
529	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	0.7	0
530	Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6246.	1.8	8
531	Immune-related cutaneous adverse events due to checkpoint inhibitors. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 613-622.	0.5	12
532	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
533	Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3069-3080.	2.0	31
534	Monitoring Immunotherapy With Optical Molecular Imaging. <i>ChemMedChem</i> , 2021, 16, 2547-2557.	1.6	6
535	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
536	Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
537	Why are immune adverse events so common with checkpoint inhibitor therapy?. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 608-610.	0.5	4
538	Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. <i>Insights Into Imaging</i> , 2021, 12, 76.	1.6	35

#	ARTICLE	IF	CITATIONS
539	Spatially Localized Immunotherapy: A Perfect Combination With Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 507-509.	0.4	1
540	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. Translational Lung Cancer Research, 2021, 10, 2752-2765.	1.3	5
541	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 703893.	1.3	33
542	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. BMC Medical Informatics and Decision Making, 2021, 21, 205.	1.5	15
543	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Safety, 2021, 44, 957-971.	1.4	38
544	Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. World Journal of Clinical Cases, 2021, 9, 4415-4422.	0.3	7
545	Chimeric antigen receptor <sup>T</sup>-cells safety: A pharmacovigilance and meta-analysis study. American Journal of Hematology, 2021, 96, 1101-1111.	2.0	14
546	Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 2198-2204.	0.8	19
547	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 2021, 13, 2931.	1.7	19
548	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
549	Immune checkpoint inhibitors: current status. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002954.	0.8	1
550	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 3014-3028.	1.3	9
551	Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Annals of Translational Medicine, 2021, 9, 1037-1037.	0.7	30
552	Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. International Immunopharmacology, 2021, 95, 107498.	1.7	45
553	Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardio-Oncology, 2021, 7, 26.	0.8	3
554	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
555	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	1.3	16
556	CX-072 (pacmilimab), a Probody<sup>®</sup>-PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26

#	ARTICLE	IF	CITATIONS
557	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
558	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	21.5	120
559	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
560	Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review. Lupus, 2021, 30, 1849-1855.	0.8	5
561	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329.	3.0	64
562	Immunotherapy in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2115-2127.	0.8	33
563	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e8.	0.8	6
564	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. Journal of Inflammation Research, 2021, Volume 14, 3077-3088.	1.6	5
565	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clinical Reviews in Allergy and Immunology, 2022, 62, 413-431.	2.9	6
566	Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. Frontiers in Immunology, 2021, 12, 682262.	2.2	13
567	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. , 2021, 9, e002446.		16
568	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports, 2021, 23, 98.	1.3	34
569	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. JCO Oncology Practice, 2021, , OP.21.00140.	1.4	6
570	Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature. Journal of Medical Case Reports, 2021, 15, 336.	0.4	7
571	Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 679095.	1.3	7
572	Hemophagocytic lymphohistiocytosis due to pembrolizumab therapy for adenocarcinoma of the lung. Baylor University Medical Center Proceedings, 2021, 34, 1-2.	0.2	0
573	Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. Ear, Nose and Throat Journal, 2021, , 014556132110310.	0.4	2
574	Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. Melanoma Research, 2021, 31, 464-471.	0.6	2

#	ARTICLE	IF	CITATIONS
575	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	1.2	4
576	Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2021, 96, 107796.	1.7	12
577	Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
578	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	4
579	Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. <i>Diagnostic Cytopathology</i> , 2021, 49, 1150-1154.	0.5	1
580	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	1.0	2
581	Reinforcing the Combinational Immuno-Oncotherapy of Switching “Cold” Tumor to “Hot” by Responsive Penetrating Nanogels. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 36824-36838.	4.0	24
582	Non-invasive Detection of Immunotherapy-Induced Adverse Events. <i>Clinical Cancer Research</i> , 2021, 27, 5353-5364.	3.2	13
583	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	1.3	14
584	Deciphering the Dynamic Complexities of the Liver Microenvironment “Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). <i>AAPS Journal</i> , 2021, 23, 99.	2.2	1
585	The Need for Critical Examination of Disparities in Immunotherapy and Targeted Therapy Use Among Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1115.	3.4	2
586	A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab342.	0.3	23
587	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 <sup>+</sup> T cells and an infiltration pattern that resembles ulcerative colitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1119-1129.	1.4	11
588	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
589	Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 701951.	2.2	25
590	Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. <i>American Journal of Emergency Medicine</i> , 2021, 46, 51-55.	0.7	26
591	Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2021, 13, 1271-1282.	1.0	13
592	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46

#	ARTICLE	IF	CITATIONS
593	Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. <i>Clinical Lung Cancer</i> , 2022, 23, 34-42.	1.1	18
594	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021, 19, 328.	1.8	4
595	Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. <i>Translational Cancer Research</i> , 2021, 10, 3870-3876.	0.4	13
596	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. <i>Immunotherapy</i> , 2021, 13, 1011-1029.	1.0	8
597	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. <i>Chest</i> , 2021, 160, 731-742.	0.4	64
598	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events—Reply. <i>JAMA Oncology</i> , 2021, 7, 1574-1575.	3.4	2
599	ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO). <i>European Heart Journal Supplements</i> , 2021, 23, C128-C153.	0.0	7
601	Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e498-e505.	0.5	32
602	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52
603	Case Report: The Neuromuscular Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 714460.	1.1	12
604	The Role of Neoantigens in Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 682325.	1.3	14
605	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
606	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
607	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16
608	<sc>PD</sc> blockade: Prospectives for immunotherapy in cancer and autoimmunity. <i>IUBMB Life</i> , 2021, 73, 1293-1306.	1.5	11
609	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	1.4	10
610	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
611	Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. <i>International Immunopharmacology</i> , 2021, 98, 107818.	1.7	12

#	ARTICLE	IF	CITATIONS
612	Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. , 2021, 9, e002960.		16
613	A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis. Annals of Palliative Medicine, 2021, 10, 10083-10090.	0.5	2
614	Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers, 2021, 13, 4928.	1.7	10
615	Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886.	0.9	2
616	Patient colon and rectal operative outcomes when treated with immune checkpoint inhibitors. European Journal of Surgical Oncology, 2021, 47, 2436-2440.	0.5	2
617	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. Digestion, 2021, 102, 965-973.	1.2	2
618	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. Cancer Investigation, 2021, 39, 789-796.	0.6	5
619	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. International Journal of Cardiology, 2021, 344, 170-178.	0.8	13
620	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers, 2021, 13, 4797.	1.7	12
621	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
622	The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Frontiers in Oncology, 2021, 11, 704475.	1.3	7
623	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
624	Novel Therapies in Oncology: An Individualized Approach. AACN Advanced Critical Care, 2021, 32, 315-323.	0.6	1
625	A Case of Lung Adenocarcinoma with Pulmonary Hypertrophic Osteoarthropathy Showing Pathological Complete Response to a Pembrolizumab-Containing Chemoimmunotherapy. Case Reports in Oncology, 2021, 14, 1380-1386.	0.3	1
626	A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis. Journal of Thoracic Oncology, 2021, 16, 1440-1442.	0.5	0
627	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	1.3	12
628	Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 155, 303-306.	1.3	2
629	The promise and perils of immunotherapy. Blood Advances, 2021, 5, 3709-3725.	2.5	23

#	ARTICLE	IF	CITATIONS
630	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
631	Immune checkpoint inhibitors in melanoma. <i>Lancet, The</i> , 2021, 398, 1002-1014.	6.3	462
632	Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 299-302.	1.3	3
633	Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors. <i>European Journal of Haematology</i> , 2021, 107, 650-657.	1.1	4
634	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103434.	2.0	26
635	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. <i>Npj Precision Oncology</i> , 2021, 5, 82.	2.3	14
636	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 3-8.	0.5	9
637	Efficacy and safety profile of avelumab monotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103464.	2.0	2
638	Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 748677.	1.6	8
639	Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. <i>Gastroenterology</i> , 2021, 161, 1106-1108.	0.6	3
640	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100220.	0.6	4
641	Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Related Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	0.6	87
642	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	1.5	16
643	Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. <i>Cancer Letters</i> , 2021, 518, 49-58.	3.2	17
644	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	1.3	6
645	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	1.3	4
646	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	3.4	25
647	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	0.9	6

#	ARTICLE	IF	CITATIONS
648	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	3.4	10
649	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	1.3	62
650	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
651	Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100105.	0.1	0
652	Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies. , 2022, , 499-513.		0
653	Proteomic biomarker technology for cancer immunotherapy. , 2022, , 357-397.		0
654	Oral Immune-Related Adverse Events “ Current Concepts and their Management. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 604-609.	0.7	2
655	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
656	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	1.6	38
657	New Onset Ocular Myasthenia Gravis After Pembrolizumab Therapy: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 309-311.	0.3	3
658	Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis. , 2021, , 27-37.		0
659	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <i>Current Cancer Research</i> , 2021, , 139-173.	0.2	0
660	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
662	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	1.1	12
663	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>OncolImmunology</i> , 2021, 10, 1875639.	2.1	30
664	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
665	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	1.0	7
666	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9

#	ARTICLE	IF	CITATIONS
667	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clinical and Translational Oncology, 2020, 22, 213-222.	1.2	14
668	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs, 2020, 34, 495-503.	2.2	15
670	Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis. Canadian Journal of Cardiology, 2021, 37, 1654-1656.	0.8	5
671	Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. International Immunopharmacology, 2020, 84, 106584.	1.7	13
672	Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. International Immunopharmacology, 2020, 84, 106601.	1.7	35
673	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina Clínica, 2020, 155, 541-547.	0.3	8
674	Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Bioscience Reports, 2020, 40, .	1.1	29
675	Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. Cancer Investigation, 2021, 39, 1-5.	0.6	7
676	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opinion on Biological Therapy, 2020, 20, 1047-1059.	1.4	9
677	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 95-105.	0.4	1
678	Practical cardiovascular imaging approach to diagnose immune checkpoint inhibitor myocarditis. European Heart Journal Cardiovascular Imaging, 2021, 22, 372-374.	0.5	6
679	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61.	3.9	66
680	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Annals of Intensive Care, 2020, 10, 143.	2.2	24
681	Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1785-1806.	0.4	12
682	Anticancer Drugs and the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 732-764.	0.4	13
683	Cardio-oncology for the general physician: â€˜oldâ€™ and â€˜newâ€™ cardiovascular toxicities and how to manage them. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-11.	0.2	2
684	Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. Annals of Gastroenterology, 2020, 34, 46-52.	0.4	2
685	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biology and Medicine, 2020, 17, 599-611.	1.4	45

#	ARTICLE	IF	CITATIONS
686	Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review. <i>Current Medicinal Chemistry</i> , 2020, 27, 4673-4698.	1.2	18
687	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <i>JMIR Formative Research</i> , 2020, 4, e17898.	0.7	17
688	Predicting Onset and Continuity of Patient-Reported Symptoms in Patients Receiving Immune Checkpoint Inhibitor (ICI) Therapies Using Machine Learning. <i>Archives of Clinical and Medical Case Reports</i> , 2020, 04, .	0.0	3
689	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 576027.	1.5	20
690	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
691	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	1.6	14
692	Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity. <i>Cancers</i> , 2021, 13, 86.	1.7	14
693	Diretriz Brasileira de Cardio-oncologia “ 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1006-1043.	0.3	37
694	Adverse effects of immuno-oncology drugs“ Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. <i>Indian Journal of Cancer</i> , 2019, 56, 10.	0.2	3
695	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
696	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
697	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	2.3	393
698	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
699	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 750-757.	2.3	86
700	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	2.3	284
701	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1191-1199.	2.3	27
702	Immune Checkpoint Inhibitor-induced Fanconi Syndrome. <i>Cureus</i> , 2020, 12, e7686.	0.2	9
703	An Unusual Presentation of Inflammatory Shoulder Arthritis Associated with Nivolumab. <i>JBJS Case Connector</i> , 2021, 11, .	0.1	1

#	ARTICLE	IF	CITATIONS
704	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 686876.	1.6	9
705	Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. <i>British Journal of Ophthalmology</i> , 2023, 107, 320-323.	2.1	8
706	Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity. <i>Nature Communications</i> , 2021, 12, 5834.	5.8	58
707	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12
708	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	1.6	14
709	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
710	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
711	Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 508.	0.4	10
712	Thirty-day mortality rates after immunotherapy initiation. <i>Immunotherapy</i> , 2021, 13, 1419-1426.	1.0	2
713	Pulmonary adverse events due to immune checkpoint inhibitors: A literature review. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	0
714	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	1.3	35
715	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
716	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
717	Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04926.	0.2	2
718	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
719	The progress of immune checkpoint therapy in primary liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188638.	3.3	29
720	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. <i>Biomaterials</i> , 2021, 279, 121182.	5.7	22
722	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 231-237.	0.0	0

724	Toxicités pulmonaires des immunothérapies : évaluer et traiter. Revue Des Maladies Respiratoires Actualites, 2019, 11, S491-S501.	0.0	0
-----	---	-----	---

#	ARTICLE	IF	CITATIONS
742	Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist's Perspective. <i>Bladder Cancer</i> , 2020, 6, 425-433.	0.2	0
744	Molecular Pathology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Journal of Analytical Oncology</i> , 0, 9, 25-32.	0.1	1
747	A Case of Isolated ACTH Deficiency and Polyarthritis during Nivolumab Therapy for Gastric Cancer. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2020, 81, 1120-1126.	0.0	0
749	Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice. <i>Pharmaceutical Sciences Asia</i> , 2020, 47, 104-112.	0.2	2
750	Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case. <i>Cureus</i> , 2021, 13, e18983.	0.2	3
751	Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 377-379.	2.1	7
752	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 747416.	1.6	0
753	Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. <i>Cancer Management and Research</i> , 2021, Volume 13, 8199-8208.	0.9	9
754	Central Nervous System Disorders Associated To Immune Checkpoint Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2021, 17, .	0.2	0
755	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	1.0	20
756	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecancermedalscience</i> , 2021, 15, 1314.	0.6	1
757	An Interâ€Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer. <i>Advanced Science</i> , 2022, 9, e2103470.	5.6	9
758	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	3.4	74
759	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. <i>Aging</i> , 2020, 12, 18741-18753.	1.4	19
760	Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy. <i>Current Problems in Diagnostic Radiology</i> , 2022, 51, 86-97.	0.6	1
761	Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 172-174.	0.6	5
762	Immunotherapy induced enterocolitis and gastritis â€What to do and when?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101703.	1.0	8
763	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8

#	ARTICLE	IF	CITATIONS
770	Gastrointestinal and liver adverse effects of anti-tumoral immune therapy: from recognition to treatment. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, 195-199.	0.6	0
771	Neoadjuvant immunotherapy for resectable non-small cell lung cancer. American Journal of Cancer Research, 2021, 11, 2521-2536.	1.4	2
772	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. Gastroenterology and Hepatology, 2021, 17, 358-366.	0.2	3
773	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110562.	0.6	5
774	Gastrointestinal adverse events of immunotherapy. BJR  Open, 2021, 3, .	0.4	0
775	Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. Journal of Investigative Dermatology, 2021, , .	0.3	11
776	Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. Biomolecules, 2021, 11, 1792.	1.8	4
777	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. Biology, 2021, 10, 1206.	1.3	3
778	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances, 2021, 3, v108-v120.	0.4	6
779	Anticancer natural products targeting immune checkpoint protein network. Seminars in Cancer Biology, 2022, 86, 1008-1032.	4.3	8
780	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. , 2022, , 471-493.		0
781	Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemotherapy and Pharmacology, 2022, 89, 1-9.	1.1	10
782	From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. Therapie, 2022, 77, 197-206.	0.6	1
783	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
784	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2021, 12, 786046.	2.2	17
785	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Oncology, 2021, 11, 751159.	1.3	16
786	Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers in Pharmacology, 2021, 12, 797852.	1.6	8
787	CheckMate-067: Raising the Bar for the Next Decade in Oncology. Journal of Clinical Oncology, 2022, 40, 111-113.	0.8	8

#	ARTICLE	IF	CITATIONS
788	How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open, 2021, 6, 100317.	2.0	10
789	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 377-387.	0.8	2
790	Colitis Induced by Immune-checkpoint Inhibitors. Nihon Daicho Komonbyo Gakkai Zasshi, 2021, 74, 599-605.	0.1	0
791	Hepatobiliary and Pancreatic Adverse Events. Advances in Experimental Medicine and Biology, 2021, 1342, 339-355.	0.8	6
792	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4
793	Onkologika. , 2021, , 579-638.		0
794	Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma. Cancers, 2022, 14, 302.	1.7	15
795	Immunotherapy toxicity: identification and management. Breast Cancer Research and Treatment, 2022, 192, 1-17.	1.1	24
796	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer, 2022, 22, 55.	1.1	14
797	Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. International Immunopharmacology, 2022, 102, 108353.	1.7	19
798	Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 778185.	1.3	10
799	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers, 2022, 14, 294.	1.7	24
800	Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer, 2022, 162, 76-98.	1.3	8
801	Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature. Frontiers in Oncology, 2021, 11, 749834.	1.3	8
802	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. Frontiers in Pharmacology, 2021, 12, 770631.	1.6	23
803	Immune-related adverse events and the balancing act of immunotherapy. Nature Communications, 2022, 13, 392.	5.8	125
804	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19
805	Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy. Journal of Materials Chemistry B, 2022, 10, 1291-1300.	2.9	6

#	ARTICLE	IF	CITATIONS
806	Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 616-624.	1.9	20
807	Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 802672.	2.2	2
808	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	2.1	10
809	Relato de caso “eventos neuromusculares relacionados com inibidores de checkpoint. <i>Revista Neurociencias</i> , 0, 30, 1-12.	0.0	0
810	Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients. <i>Supportive Care in Cancer</i> , 2022, 30, 4019-4026.	1.0	10
811	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
812	Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
813	Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytab478.	0.3	8
814	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-I/PD-L1 interaction. <i>Scientific Reports</i> , 2022, 12, 303.	1.6	6
815	Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1234-1238.	0.5	1
816	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	12.5	41
817	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	2.2	31
818	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
819	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28
820	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
822	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
823	Concise synthesis and biological activity evaluation of novel pyrazinyl-aryl urea derivatives against several cancer cell lines, which can especially induce T24 apoptotic and necroptotic cell death. <i>RSC Medicinal Chemistry</i> , 2022, 13, 280-299.	1.7	1
824	Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 21-33.	1.2	3

#	ARTICLE	IF	CITATIONS
825	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. <i>Acta Neurologica Belgica</i> , 2022, 122, 823-825.	0.5	3
826	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
827	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. <i>Nanotheranostics</i> , 2022, 6, 243-255.	2.7	17
829	Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis. <i>International Heart Journal</i> , 2022, 63, 180-183.	0.5	9
830	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	1.4	34
831	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
832	Single-Cell RNA Sequencing Reveals the Altered Landscape of Immune Cells in Immune Checkpoint Inhibitor Related Myocarditis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
833	Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2844-2868.	3.3	43
834	Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. <i>Tumori</i> , 2022, 108, 609-614.	0.6	3
835	A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	0.6	3
836	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	11
837	Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, 1753.	1.6	4
838	Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. <i>Expert Review of Hematology</i> , 2022, , 1-7.	1.0	0
839	Adverse events induced by nivolumab and ipilimumab combination regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	11
840	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. <i>Current Oncology</i> , 2022, 29, 869-880.	0.9	2
841	Immunotherapy Versus Hospice: Treatment Decision-Making in the Modern Era of Novel Cancer Therapies. <i>Current Oncology Reports</i> , 2022, 24, 285-294.	1.8	2
842	Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2022, , .	3.4	0
843	Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2239-2254.	2.0	11

#	ARTICLE	IF	CITATIONS
844	Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series. <i>Cureus</i> , 2022, 14, e22070.	0.2	2
845	A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 788629.	2.2	6
846	Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, 61, 2161-2165.	0.3	8
847	Immune-related neuromuscular junction disorder after immune checkpoint inhibitor treatment. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 22.	0.2	1
848	Strategies to mitigate the toxicity of cancer therapeutics. <i>Advances in Cancer Research</i> , 2022, , 215-244.	1.9	5
849	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
850	ä,è•æŠ—è,žç~çš,,âçžæ•â†æ¬æ•âº”ç”ç©¶èž>â±•. <i>Scientia Sinica Vitae</i> , 2022, , .	0.1	1
852	Sick Sinus Syndrome: More Than a Needle-in-a-haystack Manifestation of Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, , .	0.3	1
853	Thromboembolism Adverse Events Caused by Immune Checkpoint Inhibitor Therapy: A Disproportionality Study from 2010 to 2020 based on FAERS Database. , 2022, , .		0
854	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005.	0.6	5
855	Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. <i>Cureus</i> , 2022, 14, e22295.	0.2	2
856	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	0.9	16
857	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. <i>Vaccines</i> , 2022, 10, 304.	2.1	2
858	Predictive biomarkers of immune-related adverse events. <i>Voprosy Onkologii</i> , 2022, 68, 29-33.	0.1	0
859	Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 114, 949-958.	0.7	24
860	Immune Checkpoint Inhibitorsâ€”Associated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	1.7	25
861	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	1.8	26
862	Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. <i>Cancers</i> , 2022, 14, 1248.	1.7	3

#	ARTICLE	IF	CITATIONS
863	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. American Journal of Clinical Dermatology, 2022, 23, 331-338.	3.3	16
864	Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current Oncology, 2022, 29, 1828-1839.	0.9	72
865	Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. Case Reports in Gastrointestinal Medicine, 2022, 2022, 1-4.	0.2	3
866	Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut, 2022, 71, 1412-1425.	6.1	79
867	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy, 2022, , .	1.0	4
868	Primed for toxicity: CD4+ TÂcells and immune checkpoint inhibitors. Med, 2022, 3, 155-156.	2.2	3
869	Elevated circulating memory T cells precede immunotherapy toxicities in melanoma. Trends in Cancer, 2022, , .	3.8	7
870	Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience. Frontiers in Pharmacology, 2022, 13, 837499.	1.6	1
871	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	2.2	27
872	A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related Myocarditis. CJC Open, 2022, 4, 651-655.	0.7	2
873	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. Journal of Immunotherapy, 2022, 45, 210-216.	1.2	15
874	Postâchematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors. Health Science Reports, 2022, 5, e536.	0.6	2
875	Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis. Cardio-Oncology, 2022, 8, 5.	0.8	8
876	Radiationâ€induced enterocolitis after combination therapy with palliative radiotherapy and immune checkpoint inhibitors in patients with metastatic lung cancer. Experimental and Therapeutic Medicine, 2022, 23, 336.	0.8	2
877	Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-ïB Pathway. Journal of Inflammation Research, 2022, Volume 15, 1653-1666.	1.6	15
878	Immunotherapy in cancer: A review. IP International Journal of Comprehensive and Advanced Pharmacology, 2022, 7, 27-29.	0.1	0
879	Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Journal of Immunology Research, 2022, 2022, 1-9.	0.9	20
880	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers in Oncology, 2022, 12, 836859.	1.3	25

#	ARTICLE	IF	CITATIONS
882	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	4.3	14
883	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1
884	Targeting HIF-1 $\alpha$ abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	42
885	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	1.6	10
886	Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma. <i>Cureus</i> , 2022, 14, e23926.	0.2	1
887	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. <i>Immunotherapy</i> , 2022, , .	1.0	2
888	Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 801924.	1.3	1
889	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
890	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
891	Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 99.	7.1	18
892	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 411-428.	0.8	3
893	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients. <i>Clinical Imaging</i> , 2022, 86, 31-37.	0.8	0
894	The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. <i>Translational Oncology</i> , 2022, 20, 101375.	1.7	15
895	Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?. <i>International Immunopharmacology</i> , 2022, 108, 108738.	1.7	1
896	Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 1118-1133.	1.4	16
897	Formation of necrotizing vasculitis in the patient with diffuse B-cell large cell lymphoma on immune checkpoint inhibitor (PD-1) therapy. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 83-90.	0.1	0
898	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 290-298.	0.5	3
899	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16

#	ARTICLE	IF	CITATIONS
900	Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study. BMC Cancer, 2021, 21, 1300.	1.1	2
902	Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries. Frontiers in Immunology, 2021, 12, 799077.	2.2	7
903	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World Journal of Experimental Medicine, 2021, 11, 79-92.	0.9	8
904	Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1857-1869.	3.3	9
905	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. Frontiers in Immunology, 2021, 12, 794226.	2.2	2
906	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <scp>China</scp>. Thoracic Cancer, 2022, 13, 412-422.	0.8	19
908	Evaluation of free radical scavenging with in vitro antiproliferative properties of different extracts of pluchea lanceolata (dc.) oliv. and hiern in cancer cell lines. Pharmacognosy Magazine, 2021, 17, 886.	0.3	2
909	Electrolyte Abnormalities Associated With The Use of Atezolizumab â€“ A Systematic Review. Journal of Community Hospital Internal Medicine Perspectives, 2022, 12, 35-44.	0.4	1
910	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Frontiers in Pharmacology, 2022, 13, 835510.	1.6	10
911	A roadmap for translational cancer glycoimmunology at single cell resolution. Journal of Experimental and Clinical Cancer Research, 2022, 41, 143.	3.5	5
912	The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treatment Reviews, 2022, 106, 102394.	3.4	16
913	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. Drugs, 2022, , .	4.9	3
914	Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors. Future Oncology, 2022, 18, 2289-2300.	1.1	2
915	T Cell-Mediated Targeted Delivery of Anti-PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. Cancer Immunology Research, 2022, 10, 713-727.	1.6	4
916	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. JAMA Network Open, 2022, 5, e227722.	2.8	25
917	Principles of Surgery in Head and Neck Cutaneous Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 251-262.	0.4	1
918	Sintilimab for the treatment of non-small cell lung cancer. Biomarker Research, 2022, 10, 23.	2.8	16
920	Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Experimental Cell Research, 2022, 416, 113157.	1.2	15

#	ARTICLE	IF	CITATIONS
952	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5
953	Immunotherapy-induced Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	5
954	Histological diversity of anti-PD1-induced colitis.. <i>Histology and Histopathology</i> , 2022, , 18456.	0.5	1
961	Pharmacists' role in immune-related adverse events management: real-world incidence and risk evaluation from immunotherapy. <i>International Journal of Pharmacy Practice</i> , 2022, 30, 377-382.	0.3	2
962	Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2448.	1.0	4
963	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. <i>Endocrine Practice</i> , 2022, 28, 719-731.	1.1	12
964	Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0267572.	1.1	5
965	Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. <i>Current Oncology</i> , 2022, 29, 3104-3117.	0.9	4
966	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100076.	0.7	2
967	Cardio-Oncology Considerations in Oncologic Treatment Decisions. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 237-242.	0.2	0
968	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 93-102.	0.3	6
969	Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. <i>Voprosy Onkologii</i> , 2022, 68, 188-199.	0.1	3
970	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
971	Overcoming resistance to oncolytic virus M1 by targeting PI3K-Î³ in tumor associated myeloid cells. <i>Molecular Therapy</i> , 2022, , .	3.7	1
972	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 2276.	1.7	4
974	Hyaluronidase Enhances Targeting of Hydrogel-Encapsulated Anti-CTLA-4 to Tumor Draining Lymph Nodes and Improves Anti-Tumor Efficacy. <i>Gels</i> , 2022, 8, 284.	2.1	3
975	Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
976	Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin. <i>Cancers</i> , 2022, 14, 2320.	1.7	4

#	ARTICLE	IF	CITATIONS
977	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
978	Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 75-80.	0.0	0
979	Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. <i>Cancer Reports</i> , 2022, 5, e1624.	0.6	7
980	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
981	Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 32-36.	0.6	1
982	Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 745-766.	1.8	6
983	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	3
984	Low-Salt Diet Reduces Anti-CTLA4 Mediated Systemic Immune-Related Adverse Events while Retaining Therapeutic Efficacy against Breast Cancer. <i>Biology</i> , 2022, 11, 810.	1.3	2
985	Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	7
986	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
987	Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	0
988	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. <i>Cancers</i> , 2022, 14, 2687.	1.7	10
989	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	2
990	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program. <i>Journal of Clinical Oncology</i> , 2022, 40, 3439-3452.	0.8	24
991	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
992	Cutaneous melanoma. , 2023, , 370-375.		0
994	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
995	Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8

#	ARTICLE	IF	CITATIONS
996	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. <i>Clinical Science</i> , 2022, 136, 771-785.	1.8	2
997	Drug-induced digestive tract injury: decoding some invisible offenders. <i>Human Pathology</i> , 2023, 132, 135-148.	1.1	2
998	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3107-e3114.	1.8	7
999	Role of cardiac <scp>MRI</scp> in the diagnosis of immune checkpoint inhibitorâ€associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	2.3	19
1000	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 621-632.	0.5	2
1001	Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
1002	Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitorâ€associated myocarditis. <i>Cancer Communications</i> , 2022, 42, 902-905.	3.7	5
1003	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
1004	Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1005	Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chainâ€Reaction Are Associated With Outcome andâ€High Negative Predictive Value in Immunotherapy-Treated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1078-1085.	0.5	5
1006	Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkinâ€TM's Lymphoma. <i>Cancers</i> , 2022, 14, 2936.	1.7	4
1007	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
1008	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
1009	Î³H2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6679.	1.8	4
1010	Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1011	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
1012	Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature. <i>Brain Sciences</i> , 2022, 12, 773.	1.1	7
1013	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	1.0	1

#	ARTICLE	IF	CITATIONS
1014	Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram. <i>Lung Cancer</i> , 2022, 170, 74-84.	0.9	7
1015	Treatment-Related Adverse Events of PD-1 or PD-L1 Inhibitors for Triple Negative Breast Cancer Patients: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1016	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1017	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
1018	Immune checkpoint inhibitor-related liver toxicity. <i>Clinical Liver Disease</i> , 2022, 20, 93-96.	1.0	0
1019	Monitoring Endocrine Complications of Immunotherapy: A Screening Tool. <i>Cureus</i> , 2022, , .	0.2	3
1020	Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1021	The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy. <i>Immunologic Research</i> , 2022, 70, 765-774.	1.3	1
1022	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
1023	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1024	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1445-1452.	0.5	17
1025	Adverse drug reactions associated with immune checkpoint inhibitors: an exploratory nested case-control study in a historical cohort. <i>Therapie</i> , 2022, , .	0.6	0
1027	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1028	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. <i>Journal of Immunology</i> , 2022, 209, 696-709.	0.4	14
1029	Immune checkpoint inhibitor-related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. <i>Histopathology</i> , 0, , .	1.6	4
1030	Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2022, 110, 109015.	1.7	4
1031	Recent progresses on radiotherapeutics-based treatment of cancer with two-dimensional nanomaterials. <i>Applied Materials Today</i> , 2022, 29, 101584.	2.3	1
1032	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3

#	ARTICLE	IF	CITATIONS
1033	Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy. ESC Heart Failure, 2022, 9, 3533-3542.	1.4	3
1034	Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications. Cell Cycle, 2022, 21, 2379-2386.	1.3	11
1035	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. Middle East Journal of Digestive Diseases, 2022, 14, 244-253.	0.2	1
1036	Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression. Reports, 2022, 5, 31.	0.2	0
1037	Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer. Thoracic Cancer, 0, , .	0.8	3
1038	Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World Journal of Surgical Oncology, 2022, 20, .	0.8	9
1039	Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors. Cancers, 2022, 14, 3736.	1.7	7
1040	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. Frontiers in Oncology, 0, 12, .	1.3	5
1043	Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma. Case Reports in Cardiology, 2022, 2022, 1-6.	0.1	5
1044	The â€false hopeâ€™ argument in discussions on expanded access to investigational drugs: a critical assessment. Medicine, Health Care and Philosophy, 2022, 25, 693-701.	0.9	1
1045	Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis. Biologics: Targets and Therapy, 0, Volume 16, 119-127.	3.0	1
1046	Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab. Liver Cancer, 2022, 11, 572-575.	4.2	2
1047	Checking ovarian reserves after checkpoint blockade. Nature Cancer, 2022, 3, 907-908.	5.7	3
1048	Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Immunology, Immunotherapy, 2023, 72, 591-598.	2.0	4
1049	Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. Journal of Cardiology, 2023, 81, 63-67.	0.8	8
1050	Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. Frontiers in Oncology, 0, 12, .	1.3	3
1051	Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
1052	Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review. Frontiers in Oncology, 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1053	Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1054	Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. <i>European Journal of Cancer</i> , 2022, 177, 197-205.	1.3	8
1055	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
1056	Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1057	Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 231-235.	1.0	3
1058	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. <i>European Journal of Cancer</i> , 2022, 174, 113-120.	1.3	9
1059	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	1.7	16
1060	The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1061	Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. <i>Immunotherapy</i> , 2022, 14, 1097-1107.	1.0	3
1062	Research progress of neoantigens in gynecologic cancers. <i>International Immunopharmacology</i> , 2022, 112, 109236.	1.7	5
1063	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
1064	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
1065	Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy. <i>Internal Medicine</i> , 2023, 62, 1319-1322.	0.3	3
1066	Immunotherapy Adverse Events. <i>Current Clinical Pathology</i> , 2022, , 25-30.	0.0	0
1067	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <i>Current Clinical Pathology</i> , 2022, , 91-111.	0.0	0
1068	Cardiology (Heart). , 2022, , 7-27.		0
1069	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
1070	Diagnostic Methods of Cardiac Immunotherapy Damaging. <i>Current Clinical Pathology</i> , 2022, , 51-61.	0.0	0

#	ARTICLE	IF	CITATIONS
1071	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. Chemical Science, 2022, 13, 10897-10903.	3.7	8
1072	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. Cancer Control, 2022, 29, 107327482211112.	0.7	17
1073	Pulmonology (Lung). , 2022, , 275-299.		1
1074	Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity. SSRN Electronic Journal, 0, , .	0.4	0
1075	Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist. Current Clinical Pathology, 2022, , 73-89.	0.0	0
1076	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
1077	Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges. Frontiers in Pharmacology, 0, 13, .	1.6	13
1078	Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. Diagnostics, 2022, 12, 2104.	1.3	6
1079	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	1.7	6
1080	Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study. Current Problems in Cardiology, 2023, 48, 101380.	1.1	24
1081	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. Journal of Oncology, 2022, 2022, 1-8.	0.6	1
1082	Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. Frontiers in Pharmacology, 0, 13, .	1.6	5
1083	Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	1
1084	Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. Expert Review of Anticancer Therapy, 0, , 1-10.	1.1	0
1085	Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Joint Bone Spine, 2023, 90, 105457.	0.8	3
1086	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	5
1087	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. Journal of Clinical Medicine, 2022, 11, 5611.	1.0	5
1088	Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. Acta Oncol <sup>3</sup> gica, 2022, 61, 1295-1299.	0.8	2

#	ARTICLE	IF	CITATIONS
1089	Immune checkpoint inhibitors “ the revolutionary cancer immunotherapy comes with a cardiotoxic price. Trends in Cardiovascular Medicine, 2024, 34, 71-77.	2.3	6
1090	Chinese expert consensus on diagnosis and treatment of radiation pneumonitis. Precision Radiation Oncology, 2022, 6, 262-271.	0.4	2
1091	Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Alimentary Pharmacology and Therapeutics, 2022, 56, 1370-1382.	1.9	8
1092	Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response. Journal of Oncology Pharmacy Practice, 2023, 29, 986-991.	0.5	2
1093	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. European Journal of Endocrinology, 2022, 187, G1-G21.	1.9	35
1094	A case of cytokine release syndrome accompanied with <scp>COVID</scp>â€“19 infection during treatment with immune checkpoint inhibitors for nonâ€“small cell lung cancer. Thoracic Cancer, 2022, 13, 2911-2914.	0.8	6
1095	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. Frontiers in Immunology, 0, 13, .	2.2	10
1096	Long-Term Cardiovascular Mortality among 80,042 Older Patients with Bladder Cancer. Cancers, 2022, 14, 4572.	1.7	4
1097	Myocarditis Induced by Immunotherapy in Metastatic Melanomaâ€“Review of Literature and Current Guidelines. Journal of Clinical Medicine, 2022, 11, 5182.	1.0	2
1098	Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature. Frontiers in Immunology, 0, 13, .	2.2	3
1099	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2235-2242.	1.2	4
1100	Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. Frontiers in Immunology, 0, 13, .	2.2	7
1101	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Frontiers in Immunology, 0, 13, .	2.2	12
1102	Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Melanoma Research, 2022, 32, 451-459.	0.6	3
1103	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	5
1104	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. Current Treatment Options in Oncology, 2022, 23, 1428-1442.	1.3	1
1105	An exploratory cross-sectional study of immune checkpoint inhibitors and immuno-related adverse events: Knowledge and influencing factors among Japanese oncology nurses. Asia-Pacific Journal of Oncology Nursing, 2023, 10, 100147.	0.7	3
1106	Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A <scp>singleâ€“center</scp> case series. Cancer Medicine, 0, , .	1.3	6

#	ARTICLE	IF	CITATIONS
1107	Anti-PD-1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
1108	Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. , 2022, 10, e005323.		16
1109	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1110	Circulating biomarkers of response to immunotherapy and immune-related adverse events. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 855-865.	1.5	2
1111	Cancer metastasis chemoprevention prevents circulating tumour cells from germination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	9
1112	Pathogenesis of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Advances in Clinical Medicine</i> , 2022, 12, 8888-8893.	0.0	0
1113	A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1114	Evaluation of Knowledge of Immunotherapy Toxicities Among Emergency Physicians in Riyadh, Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	0
1115	Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211332.	0.4	2
1116	The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 1389-1398.	0.6	11
1118	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1119	MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. <i>Cancers</i> , 2022, 14, 5011.	1.7	2
1121	Imaging of Drug-Related Pneumonitis in Oncology. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
1122	Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1275-1287.	1.0	4
1123	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. <i>OncoImmunology</i> , 2022, 11, .	2.1	14
1124	Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor. <i>Journal of Neurosciences in Rural Practice</i> , 0, .	0.3	0
1125	Clinical cancer immunotherapy: Current progress and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39
1126	Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	0

#	ARTICLE	IF	CITATIONS
1127	Clustering using unsupervised machine learning can stratify the risk of immune-related liver injury. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	2
1128	Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncology, 2022, 8, 1794.	3.4	33
1129	Quality and content evaluation of websites with information about immune checkpoint inhibitors: An environmental scan. PLoS ONE, 2022, 17, e0275676.	1.1	1
1130	Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 4933.	1.7	5
1131	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 1217-1238.	0.6	204
1132	Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light. Current Treatment Options in Oncology, 2022, 23, 1777-1792.	1.3	6
1133	Limitations of Immunotherapy in Cancer. Cureus, 2022, , .	0.2	2
1134	Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis. Current Opinion in Oncology, 2023, 35, 31-36.	1.1	0
1135	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. OncoImmunology, 2022, 11, .	2.1	3
1136	Immune Checkpoint Inhibitors Related to Cardiotoxicity. Journal of Cardiovascular Development and Disease, 2022, 9, 378.	0.8	3
1137	Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis. European Journal of Radiology, 2022, 156, 110558.	1.2	0
1138	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers, 2022, 14, 5403.	1.7	7
1139	Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-“Small Cell Lung Cancer. Radiographics, 2022, 42, 1956-1974.	1.4	4
1140	Nanomedicine for advanced cancer immunotherapy. Journal of Controlled Release, 2022, 351, 1017-1037.	4.8	7
1141	Reactivation of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma. Siberian Journal of Oncology, 2022, 21, 162-167.	0.1	1
1142	A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research, 2023, 281, 289-298.	0.8	3
1143	Clinical significance of interstitial lung abnormalities and immune checkpoint <scp>inhibitor-induced</scp> interstitial lung disease in patients with <scp>non-small</scp> cell lung cancer. Thoracic Cancer, 2023, 14, 73-80.	0.8	3
1144	PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. Frontiers in Pharmacology, 0, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
1145	T cells specific for Î±-myosin drive immunotherapy-related myocarditis. <i>Nature</i> , 2022, 611, 818-826.	13.7	100
1146	Artificial intelligence for prediction of response to cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 87, 137-147.	4.3	12
1147	Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1149	Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 5489.	1.7	4
1151	Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1152	Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. <i>Cancer</i> , 2023, 129, 367-375.	2.0	4
1154	The novel diagnostic index based on HLA-DRB1 genotype and PD-L1 expression can predict severe irAEs in patients with metastatic melanoma taking immune checkpoint inhibitors. <i>Critical Reviews in Immunology</i> , 2022, , .	1.0	0
1155	Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. , 2022, , .		0
1156	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0
1157	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
1158	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2289-2305.	1.3	6
1159	Cardiotoxicidade associada aos inibidores de checkpoint: relato de caso. <i>Brazilian Journal of Health Review</i> , 2022, 5, 23192-23203.	0.0	0
1160	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	1.7	3
1161	Multisystem immune-related adverse events due to toripalimab: Two cases-based review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1162	Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. <i>Medicine (United States)</i> , 2022, 101, e31873.	0.4	4
1163	Changes of IL-6 And IFN-Î³ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31761.	0.4	2
1164	The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	7
1165	Acetylcholine receptor binding antibodyâ€“associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
1166	Supportive Care and Palliative Care for Lung Cancer in Long-term Survival Era. Japanese Journal of Lung Cancer, 2022, 62, 927-930.	0.0	0
1167	Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. Frontiers in Immunology, 0, 13, .	2.2	4
1168	Checkpoint inhibitors are a basic scienceâ€based, transformative new treatment for lung cancer. Respirology, 2023, 28, 101-106.	1.3	2
1169	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer, 2022, 22, .	1.1	1
1170	Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. Npj Genomic Medicine, 2022, 7, .	1.7	8
1172	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. JACC: CardioOncology, 2022, 4, 635-645.	1.7	4
1173	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. Endocrinology and Metabolism, 2022, 37, 839-850.	1.3	3
1174	Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine, 2022, 28, 2584-2591.	15.2	38
1175	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1176	Approach to the Patient With Immune Checkpoint Inhibitorâ€Associated Endocrine Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1514-1525.	1.8	8
1177	Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitorâ€Induced Myocarditis. JACC: CardioOncology, 2022, 4, 689-700.	1.7	19
1178	Unchecked autoreactive CD8+ T cells wreak havoc in cancer immunotherapy. , 2022, 1, 1111-1113.		2
1179	Immune-related adverse events: A bibliometric analysis. Frontiers in Immunology, 0, 13, .	2.2	10
1181	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targeted Oncology, 2023, 18, 147-158.	1.7	2
1182	Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. Current Problems in Cancer, 2022, , 100934.	1.0	0
1183	Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. BMJ Case Reports, 2022, 15, e251966.	0.2	4
1184	A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?. JACC: CardioOncology, 2022, 4, 670-672.	1.7	1
1185	Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation. JACC: CardioOncology, 2022, 4, 727-730.	1.7	6

#	ARTICLE	IF	CITATIONS
1186	Immune Checkpoint Inhibitor Myocarditis—Treatment Strategies and—Future Directions. JACC: CardioOncology, 2022, 4, 704-707.	1.7	12
1187	Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report. World Journal of Clinical Cases, 0, 10, 13108-13114.	0.3	1
1188	Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint—inhibitor pneumonitis: A case report and literature review. Cancer Reports, 0, , .	0.6	3
1189	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
1190	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology, 0, 13, .	1.6	13
1191	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. Frontiers in Veterinary Science, 0, 9, .	0.9	4
1192	Late—onset immune checkpoint inhibitor—related pneumonitis after cessation of sintilimab: A case report and literature review. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	1
1193	Microbiome influencers of checkpoint blockade—associated toxicity. Journal of Experimental Medicine, 2023, 220, .	4.2	13
1194	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology, 0, 13, .	2.2	3
1195	Neutrophil elastase: From mechanisms to therapeutic potential. Journal of Pharmaceutical Analysis, 2023, 13, 355-366.	2.4	11
1196	Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis. Clinical Immunology, 2023, 247, 109230.	1.4	1
1197	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology Research, 2023, 53, 450-459.	1.8	2
1198	A New Look at Cancer Immunotherapy via Artificial Intelligence. , 2023, , 1-18.		0
1199	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
1200	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. Frontiers in Oncology, 0, 12, .	1.3	3
1201	Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation. BMC Medicine, 2023, 21, .	2.3	2
1202	Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. , 2023, , 269-287.		1
1203	The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Translational Oncology, 2023, 28, 101619.	1.7	8

#	ARTICLE	IF	CITATIONS
1204	Checkpoint inhibitor induced myositis – The value of MRI STIR. ENeurologicalSci, 2023, 30, 100442.	0.5	3
1205	Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Cancers, 2023, 15, 240.	1.7	5
1206	Methodological Approaches to Studying Fatal Adverse Drug Reactions. Safety and Risk of Pharmacotherapy, 2022, 10, 381-395.	0.1	0
1207	Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	6
1208	A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. Frontiers in Oncology, 0, 13, .	1.3	2
1209	Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data. Cancer Research Communications, 2023, 3, 258-266.	0.7	0
1210	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients – Survival: Single Center Experience and Literature Review. Cancers, 2023, 15, 888.	1.7	5
1211	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. Medicina (Lithuania), 2023, 59, 215.	0.8	2
1212	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
1213	Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases. International Journal of Cardiovascular Practice, 2023, 7, .	0.2	0
1214	Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFN $\gamma$ Responses of HIV-Infected Persons on Antiretroviral Therapy. Vaccines, 2023, 11, 211.	2.1	0
1215	Case report: A rare case of sintilimab-induced gastric stenosis and literature review. Frontiers in Oncology, 0, 13, .	1.3	1
1217	Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. Frontiers in Oncology, 0, 12, .	1.3	0
1218	Immune-Related Adverse Events of the Gastrointestinal System. Cancers, 2023, 15, 691.	1.7	1
1219	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers – Emerging Strategies for Clinical Management. Transplantation, 2023, 107, 1452-1462.	0.5	7
1220	Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. Eye, 2023, 37, 2482-2487.	1.1	7
1221	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	3
1222	Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. Clinical Therapeutics, 2023, 45, 151-159.	1.1	3

#	ARTICLE	IF	CITATIONS
1223	Association between <sc>PD</sc> â€¹ inhibitorsâ€²-related adverse events and frailty assessed by frailty index in lung cancer patients. Cancer Medicine, 0, , .	1.3	1
1224	Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Medicine, 0, , .	1.3	4
1225	Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. Cancer Immunology, Immunotherapy, 2023, 72, 2169-2178.	2.0	1
1226	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. Praxis, 2023, 112, 160-171.	0.2	1
1227	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. BMC Cancer, 2023, 23, .	1.1	0
1228	Imaging Recommendations for Diagnosis, Staging and Management of Treatment-Related Complications in Cancer. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
1229	Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. International Journal of Molecular Sciences, 2023, 24, 6052.	1.8	2
1230	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. Current Oncology Reports, 2023, 25, 743-751.	1.8	2
1231	Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC. Journal of Thoracic Oncology, 2023, 18, 896-906.	0.5	3
1232	Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer. Current Oncology Reports, 2023, 25, 735-742.	1.8	3
1233	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
1234	Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America, 2023, 107, 623-640.	1.1	0
1235	Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors. European Journal of Cancer, 2023, 184, 124-136.	1.3	7
1236	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. International Immunopharmacology, 2023, 119, 110158.	1.7	2
1237	Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?. European Journal of Cancer, 2023, 186, 166-171.	1.3	7
1238	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
1239	Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med, 2023, 4, 113-129.e7.	2.2	31
1240	Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis. Frontiers in Pharmacology, 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
1241	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
1242	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 2769.	1.8	7
1243	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1244	Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. Journal of the Endocrine Society, 2023, 7, .	0.1	8
1245	A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry. Cureus, 2023, , .	0.2	0
1246	Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database. Clinical Drug Investigation, 2023, 43, 177-184.	1.1	2
1247	Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis. Diagnostics, 2023, 13, 691.	1.3	1
1248	Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis. World Journal of Gastrointestinal Oncology, 0, 15, 352-367.	0.8	0
1249	&lt;italic&gt;Salmonella typhimurium&lt;/italic&gt; may support cancer treatment: a review. Acta Biochimica Et Biophysica Sinica, 2023, 55, 331-342.	0.9	2
1250	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon, 2023, 9, e13725.	1.4	0
1251	Cellular Atlas of Senescent Lineages in Radiation- or Immunotherapy-Induced Lung Injury by Single-Cell RNA-Sequencing Analysis. International Journal of Radiation Oncology Biology Physics, 2023, 116, 1175-1189.	0.4	3
1252	Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis. Frontiers in Immunology, 0, 14, .	2.2	2
1253	Peripheral nervous system adverse events associated with immune checkpoint inhibitors. Journal of Neurology, 2023, 270, 2975-2986.	1.8	3
1254	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers, 2023, 15, 1324.	1.7	1
1255	The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. International Immunopharmacology, 2023, 117, 109895.	1.7	3
1256	Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. Oncologist, 2023, 28, e379-e390.	1.9	4
1257	Advances in immune checkpoint inhibitors induced-cardiotoxicity. Frontiers in Immunology, 0, 14, .	2.2	2
1258	Imaging assessment of toxicity related to immune checkpoint inhibitors. Frontiers in Immunology, 0, 14, .	2.2	6

#	ARTICLE	IF	CITATIONS
1259	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	7.7	40
1260	Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors. , 2023, , 1-18.		0
1261	Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. <i>Cancers</i> , 2023, 15, 1458.	1.7	3
1262	Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4 and PD-1-targeted immunotherapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	4
1263	Endocrine and Neurological Toxicities of Immunotherapies. <i>Praxis</i> , 2023, 112, 178-183.	0.2	1
1265	Management of the adverse effects of cancer immunotherapy with a focus on the respiratory and nervous systems. <i>Journal of the Korean Medical Association</i> , 2023, 66, 116-122.	0.1	0
1266	Immunotherapy and Gastrointestinal Toxicities. <i>Praxis</i> , 2023, 112, 172-177.	0.2	1
1267	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
1268	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
1269	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. <i>BMC Neurology</i> , 2023, 23, .	0.8	1
1271	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1273	Eosinophil and IFN- $\gamma$ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1274	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1275	Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2023, 55, 1621-1631.	0.4	1
1276	Supply chain agility and performance: evidence from a meta-analysis. <i>International Journal of Operations and Production Management</i> , 2023, 43, 1587-1633.	3.5	4
1277	Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. <i>Future Oncology</i> , 2023, 19, 259-270.	1.1	1
1278	Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations. <i>Oncolimmunology</i> , 2023, 12, .	2.1	0
1279	Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. <i>Oncology and Therapy</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1280	Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
1281	Assessment of Symptoms and Adverse Events Related to Immunotherapy in Patients With Cancer: An Integrative Review. <i>Journal of Pain and Symptom Management</i> , 2023, , .	0.6	0
1282	Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. <i>Revue Neurologique</i> , 2023, 179, 506-515.	0.6	5
1283	Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. <i>Expert Opinion on Drug Safety</i> , 2024, 23, 99-105.	1.0	1
1284	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
1285	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1286	Two Cases of Immune Checkpoint Inhibitor-Induced Myocarditis With Complete Atrioventricular Block. <i>Cureus</i> , 2023, , .	0.2	0
1287	Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1288	Toxicity When Combining Immunotherapy and Radiotherapy. , 2023, , 1-32.		0
1289	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. <i>European Journal of Cancer</i> , 2023, 187, 36-57.	1.3	1
1290	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
1291	Gastrointestinal Side Effects of Anticancer Therapy. , 2023, , 1-36.		0
1292	Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. <i>Diagnostics</i> , 2023, 13, 1243.	1.3	9
1293	Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1294	Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2023, 12, 252-255.	0.7	0
1295	Checkpoint Inhibitor Colitis With Superimposed <i>Clostridioides difficile</i> Infection. <i>Cureus</i> , 2023, , .	0.2	0
1296	A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors. <i>European Clinical Respiratory Journal</i> , 2023, 10, .	0.7	1
1297	Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3907-3918.	1.9	5

#	ARTICLE	IF	CITATIONS
1298	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€œ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	0.7	81
1299	Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers, 2023, 15, 2170.	1.7	0
1300	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
1301	Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins. , 2024, , 726-841.		0
1302	Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of careâ€”A North Queensland perspective. Australian Journal of Rural Health, 0, , .	0.7	0
1303	Cutaneous manifestations induced by check point inhibitors in 120 melanoma patientsâ€”The European MelSkinTox study. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1606-1615.	1.3	3
1305	Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study. Frontiers in Pharmacology, 0, 14, .	1.6	0
1306	A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. BMC Pulmonary Medicine, 2023, 23, .	0.8	3
1307	The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. Frontiers in Oncology, 0, 13, .	1.3	2
1308	Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis. Cancers, 2023, 15, 2329.	1.7	1
1309	The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. Cancers, 2023, 15, 2319.	1.7	1
1310	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety, 2024, 23, 257-267.	1.0	0
1311	Immune Checkpoint Inhibitors â€” The Need for Innovation. New England Journal of Medicine, 2023, 388, 1529-1532.	13.9	7
1312	Mortality associated with the development of acute liver failure after a single dose of nivolumab. Clinical Journal of Gastroenterology, 0, , .	0.4	1
1313	Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review. , 2023, 6, 100036.		4
1314	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
1315	Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department. Cancer Medicine, 2023, 12, 12462-12469.	1.3	1
1316	Risk Factors for Immune Checkpoint Inhibitorâ€Mediated Cardiovascular Toxicities. Current Oncology Reports, 2023, 25, 753-763.	1.8	3

1318	Extensive CARDioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals, 2023, 16, 625.	1.7	1
1319	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. Quantitative Imaging in Medicine and Surgery, 2023, .	1.1	1
1330	Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report. Frontiers in Pharmacology, 0, 14, .	1.6	1
1342	Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clinical and Translational Oncology, 2023, 25, 3073-3085.	1.2	2
1346	Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain. Frontiers in Immunology, 0, 14, .	2.2	1
1365	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety, 2023, 46, 819-833.	1.4	2
1369	Arzneimittel- und MedizinproduktschÄden â€“ Begutachtung. Springer Reference Medizin, 2023, , 1-15.	0.0	0
1389	Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. International Review of Cell and Molecular Biology, 2024, , 181-206.	1.6	0
1394	SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors. Cell Death and Disease, 2023, 14, .	2.7	3
1398	Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. Cancer Chemotherapy and Pharmacology, 2023, 92, 165-179.	1.1	0
1427	Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies. Discover Oncology, 2023, 14, .	0.8	1
1429	Nano-Biofortified Crop Plants with Zinc for Human Health. , 2023, , 53-76.		0
1435	Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
1444	Role of echocardiography in patients treated with immune checkpoints inhibitors. Journal of Echocardiography, 0, , .	0.4	0
1450	è„ç˜ç¸Œ...³çšš„ä‰ç°§æ·‹âˆ·ç»œ“æžš„çšš„æ£€æµ•â€™Œé†ŒŒ–âˆ†æžš. Journal of Zhejiang University: Science B, 2023, 24, 739-795. 1		
1455	Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion. Advances in Therapy, 2023, 40, 5579-5590.	1.3	0
1458	Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer. Current Oncology, 2023, 30, 7802-7809.	0.9	1

#	ARTICLE	IF	CITATIONS
1465	Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
1479	Cancer Among the Elderly. , 2023, , 1-31.		0
1499	Progress in systemic therapy for advanced-stage urothelial carcinoma. Nature Reviews Clinical Oncology, 2024, 21, 8-27.	12.5	1
1509	Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma. , 2023, , 195-229.		0
1529	Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. Current Dermatology Reports, 2023, 12, 225-232.	1.1	0
1538	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
1540	Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report. Cancer Chemotherapy and Pharmacology, 0, , .	1.1	1
1544	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discover Oncology, 2024, 15, .	0.8	1
1553	Antibody-Based Biotherapeutics in Cancer. , 2024, , 547-589.		0
1558	Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab. Clinical Journal of Gastroenterology, 2024, 17, 307-310.	0.4	0
1560	Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management. Pharmaceutical Medicine, 2024, 38, 25-38.	1.0	0
1586	Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. Clinical and Translational Imaging, 2024, 12, 187-195.	1.1	0
1593	Clinical and translational attributes of immune-related adverse events. Nature Cancer, 2024, 5, 557-571.	5.7	0
1595	Case Report: Sudden very late-onset near fatal PD1 inhibitor-associated myocarditis with out-of-hospital cardiac arrest after >2.5 years of pembrolizumab treatment. Frontiers in Cardiovascular Medicine, 0, 11, .	1.1	0
1598	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
1619	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.0	0